Cargando…
RiMINI – the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial
BACKGROUND: Hepatic encephalopathy (HE) is a clinically significant complication of liver cirrhosis impacting on the patients’ quality of life. Minimal hepatic encephalopathy (MHE) is diagnosed by psychometric tests, found in up to 80 % of patients with liver cirrhosis and carries a high risk of pro...
Autores principales: | Schulz, Christian, Schütte, Kerstin, Kropf, Siegfried, Schmitt, Friedhelm C., Vasapolli, Riccardo, Kliegis, Leon M., Riegger, Antonia, Malfertheiner, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770677/ https://www.ncbi.nlm.nih.gov/pubmed/26926775 http://dx.doi.org/10.1186/s13063-016-1205-8 |
Ejemplares similares
-
Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013) -
Francesca da Rimini : highlights /
por: Zandonai, Riccardo, 1883-1944
Publicado: (1991) -
Efficacy of Zinc Supplement in Minimal hepatic Encephalopathy: A prospective, Randomized Controlled Study (Zinc-MHE Trial)
por: Janyajirawong, Rattaya, et al.
Publicado: (2021) -
Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011) -
The Use of Rifaximin in Patients With Cirrhosis
por: Caraceni, Paolo, et al.
Publicado: (2021)